Association of Cardiovascular Events with COVID-19 Vaccines Using Vaccine Adverse Event Reporting System (VAERS): A Retrospective Study.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY Current drug safety Pub Date : 2024-01-01 DOI:10.2174/0115748863276904231108095255
Mohd Amir, S Latha, Ruchika Sharma, Anoop Kumar
{"title":"Association of Cardiovascular Events with COVID-19 Vaccines Using Vaccine Adverse Event Reporting System (VAERS): A Retrospective Study.","authors":"Mohd Amir, S Latha, Ruchika Sharma, Anoop Kumar","doi":"10.2174/0115748863276904231108095255","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 vaccines have played a crucial role in reducing the burden of the global pandemic. However, recent case reports have indicated the association of the COVID- 19 vaccines with cardiovascular events but the exact association is unclear so far.</p><p><strong>Objective: </strong>Therefore, the objective of the current study is to find out the association of cardiovascular events with COVID-19 vaccines.</p><p><strong>Methods: </strong>The COVID-19 Vaccine Knowledge Base (Cov19VaxKB) tool was used to query the Vaccine Adverse Event Reporting System (VAERS) database. The proportional reporting ratio [PRR (≥2)] with associated chi-squared value (>4), and the number of cases > 0.2% of total reports, was used to assess the association of COVID-19 vaccines with cardiovascular events.</p><p><strong>Results: </strong>A total of 33,754 cases of cardiovascular events associated with COVID-19 vaccines were found in the Cov19VaxKB tool. The cases were observed in different age groups (18-64, and 65 years and above) and gender. The disproportionality measures indicate a statistically significant association between cardiovascular events and COVID-19 vaccines.</p><p><strong>Conclusion: </strong>The current study identified a signal of various cardiovascular events with the COVID-19 vaccines. However, further causality assessment is required to confirm the association.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863276904231108095255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 vaccines have played a crucial role in reducing the burden of the global pandemic. However, recent case reports have indicated the association of the COVID- 19 vaccines with cardiovascular events but the exact association is unclear so far.

Objective: Therefore, the objective of the current study is to find out the association of cardiovascular events with COVID-19 vaccines.

Methods: The COVID-19 Vaccine Knowledge Base (Cov19VaxKB) tool was used to query the Vaccine Adverse Event Reporting System (VAERS) database. The proportional reporting ratio [PRR (≥2)] with associated chi-squared value (>4), and the number of cases > 0.2% of total reports, was used to assess the association of COVID-19 vaccines with cardiovascular events.

Results: A total of 33,754 cases of cardiovascular events associated with COVID-19 vaccines were found in the Cov19VaxKB tool. The cases were observed in different age groups (18-64, and 65 years and above) and gender. The disproportionality measures indicate a statistically significant association between cardiovascular events and COVID-19 vaccines.

Conclusion: The current study identified a signal of various cardiovascular events with the COVID-19 vaccines. However, further causality assessment is required to confirm the association.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用疫苗不良事件报告系统(VAERS)的心血管事件与COVID-19疫苗的关联:一项回顾性研究
背景:COVID-19疫苗在减轻全球大流行负担方面发挥了至关重要的作用。然而,最近的病例报告表明COVID- 19疫苗与心血管事件有关,但目前尚不清楚确切的联系。目的:因此,本研究的目的是了解心血管事件与COVID-19疫苗的关系。方法:采用COVID-19疫苗知识库(Cov19VaxKB)工具查询疫苗不良事件报告系统(VAERS)数据库。采用相关卡方值(>4)且病例数>总报告数的比例报告比[PRR(≥2)],评估COVID-19疫苗与心血管事件的相关性。结果:在Cov19VaxKB工具中共发现了33754例与COVID-19疫苗相关的心血管事件。病例分布在不同年龄组(18-64岁,65岁及以上)和性别。歧化测量表明,心血管事件与COVID-19疫苗之间存在统计学上显著的关联。结论:目前的研究确定了COVID-19疫苗可引起各种心血管事件的信号。然而,需要进一步的因果关系评估来证实这种关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
期刊最新文献
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome with Multiple Drugs (Leflunomide and Cefuroxime): A Case Report. Possible Terbinafine and/or Itraconazole Induced Vasculitis - A Case Study. Long-term Safety Monitoring and Efficacy Status of Infliximab and its Biosimilars in Psoriasis Management. Parsonage-Turner Syndrome Following AstraZeneca COVID-19 Vaccination. Ciprofloxacin's Structure Causing Fluoride-Related Toxicity: A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1